Is XENE or MAZE more profitable?

Maze Therapeutics' return on equity of -34.94% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Xenon Pharmaceuticals N/A -43.98% -41.72% Maze Therapeutics N/A -34.94% -30.18%

Does the media favor XENE or MAZE?

In the previous week, Xenon Pharmaceuticals and Xenon Pharmaceuticals both had 4 articles in the media. Xenon Pharmaceuticals' average media sentiment score of 1.24 beat Maze Therapeutics' score of 1.21 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MAZE or PTCT?

In the previous week, PTC Therapeutics had 10 more articles in the media than Maze Therapeutics. MarketBeat recorded 14 mentions for PTC Therapeutics and 4 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.21 beat PTC Therapeutics' score of 0.77 indicating that Maze Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MAZE or LGND?

In the previous week, Maze Therapeutics and Maze Therapeutics both had 4 articles in the media. Maze Therapeutics' average media sentiment score of 1.21 beat Ligand Pharmaceuticals' score of 0.40 indicating that Maze Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TVTX or MAZE?

In the previous week, Travere Therapeutics had 7 more articles in the media than Maze Therapeutics. MarketBeat recorded 11 mentions for Travere Therapeutics and 4 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.21 beat Travere Therapeutics' score of 1.18 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Maze Therapeutics (MAZE) Competitors

$29.43 +0.50 (+1.73%)

As of 08/21/2026 04:00 PM Eastern

Compare

MAZE vs. XENE, KNSA, PTCT, LGND, and TVTX

Should you buy Maze Therapeutics stock or one of its competitors? Maze Therapeutics's main competitors and comparable companies include Xenon Pharmaceuticals (XENE), Kiniksa Pharmaceuticals International (KNSA), PTC Therapeutics (PTCT), Ligand Pharmaceuticals (LGND), and Travere Therapeutics (TVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Maze Therapeutics compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Maze Therapeutics (NASDAQ:MAZE) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

In the previous week, Xenon Pharmaceuticals and Xenon Pharmaceuticals both had 4 articles in the media. Xenon Pharmaceuticals' average media sentiment score of 1.24 beat Maze Therapeutics' score of 1.21 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maze Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	783.28	-$345.91M	-$4.74	N/A
Maze Therapeutics	$167.50M	9.76	-$131.12M	-$2.52	N/A

Xenon Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market.

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Maze Therapeutics' return on equity of -34.94% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
Maze Therapeutics	N/A	-34.94%	-30.18%

Xenon Pharmaceuticals currently has a consensus price target of $77.13, indicating a potential upside of 26.93%. Maze Therapeutics has a consensus price target of $66.00, indicating a potential upside of 124.26%. Given Maze Therapeutics' higher possible upside, analysts clearly believe Maze Therapeutics is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Maze Therapeutics beats Xenon Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Maze Therapeutics compare to Kiniksa Pharmaceuticals International?

Maze Therapeutics (NASDAQ:MAZE) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Maze Therapeutics has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.05, meaning that its share price is 95% less volatile than the broader market.

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 5.3% of Maze Therapeutics shares are held by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Maze Therapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-34.94%	-30.18%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

Kiniksa Pharmaceuticals International has higher revenue and earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	9.76	-$131.12M	-$2.52	N/A
Kiniksa Pharmaceuticals International	$677.56M	9.10	$59.01M	$0.97	81.47

In the previous week, Maze Therapeutics had 3 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 4 mentions for Maze Therapeutics and 1 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.63 beat Maze Therapeutics' score of 1.21 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Maze Therapeutics currently has a consensus target price of $66.00, suggesting a potential upside of 124.26%. Kiniksa Pharmaceuticals International has a consensus target price of $87.38, suggesting a potential upside of 10.56%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Maze Therapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Kiniksa Pharmaceuticals International beats Maze Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Maze Therapeutics compare to PTC Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

PTC Therapeutics has higher revenue and earnings than Maze Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	9.76	-$131.12M	-$2.52	N/A
PTC Therapeutics	$1.01B	5.78	$682.64M	-$0.58	N/A

In the previous week, PTC Therapeutics had 10 more articles in the media than Maze Therapeutics. MarketBeat recorded 14 mentions for PTC Therapeutics and 4 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.21 beat PTC Therapeutics' score of 0.77 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maze Therapeutics has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Maze Therapeutics currently has a consensus price target of $66.00, suggesting a potential upside of 124.26%. PTC Therapeutics has a consensus price target of $98.55, suggesting a potential upside of 41.14%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Maze Therapeutics is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64

Maze Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -3.80%. Maze Therapeutics' return on equity of -34.94% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-34.94%	-30.18%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

Summary

Maze Therapeutics beats PTC Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Maze Therapeutics compare to Ligand Pharmaceuticals?

Maze Therapeutics (NASDAQ:MAZE) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Maze Therapeutics currently has a consensus price target of $66.00, indicating a potential upside of 124.26%. Ligand Pharmaceuticals has a consensus price target of $335.75, indicating a potential upside of 17.28%. Given Maze Therapeutics' higher probable upside, equities analysts clearly believe Maze Therapeutics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

Ligand Pharmaceuticals has a net margin of 67.88% compared to Maze Therapeutics' net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 20.06% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-34.94%	-30.18%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

In the previous week, Maze Therapeutics and Maze Therapeutics both had 4 articles in the media. Maze Therapeutics' average media sentiment score of 1.21 beat Ligand Pharmaceuticals' score of 0.40 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ligand Pharmaceuticals has higher revenue and earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	9.76	-$131.12M	-$2.52	N/A
Ligand Pharmaceuticals	$268.09M	21.29	$124.45M	$9.35	30.62

Maze Therapeutics has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 5.3% of Maze Therapeutics shares are held by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Ligand Pharmaceuticals beats Maze Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Maze Therapeutics compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Maze Therapeutics (NASDAQ:MAZE) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Travere Therapeutics has higher revenue and earnings than Maze Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	12.62	-$25.55M	-$0.46	N/A
Maze Therapeutics	$167.50M	9.76	-$131.12M	-$2.52	N/A

Maze Therapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Maze Therapeutics' return on equity of -34.94% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-7.35%	-55.15%	-6.88%
Maze Therapeutics	N/A	-34.94%	-30.18%

In the previous week, Travere Therapeutics had 7 more articles in the media than Maze Therapeutics. MarketBeat recorded 11 mentions for Travere Therapeutics and 4 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.21 beat Travere Therapeutics' score of 1.18 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Travere Therapeutics has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market.

Travere Therapeutics currently has a consensus price target of $61.67, indicating a potential downside of 6.15%. Maze Therapeutics has a consensus price target of $66.00, indicating a potential upside of 124.26%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Maze Therapeutics is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Maze Therapeutics beats Travere Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Maze Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MAZE vs. The Competition

Export

Metric	Maze Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.63B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-11.68	11.62	272.60	24.24
Price / Sales	9.76	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	3.61	16.80	13.05	6.20
Net Income	-$131.12M	-$12.50M	$3.47B	$348.59M
7 Day Performance	8.28%	3.29%	2.09%	0.08%
1 Month Performance	6.28%	8.23%	6.64%	3.88%
1 Year Performance	118.16%	55.05%	25.02%	16.98%

Maze Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MAZE Maze Therapeutics	2.129 of 5 stars	$29.43 +1.7%	$66.00 +124.3%	+118.2%	$1.63B	$167.50M	N/A	121
XENE Xenon Pharmaceuticals	3.3921 of 5 stars	$62.35 -2.9%	$77.13 +23.7%	+56.5%	$6.03B	$7.50M	N/A	210	Positive News
KNSA Kiniksa Pharmaceuticals International	3.9637 of 5 stars	$76.75 -1.4%	$87.38 +13.8%	+134.2%	$5.99B	$677.56M	79.12	220	Positive News
PTCT PTC Therapeutics	3.8008 of 5 stars	$71.70 -0.4%	$98.55 +37.4%	+38.1%	$5.98B	$1.73B	N/A	1,410	News Coverage Positive News Analyst Downgrade Insider Trade
LGND Ligand Pharmaceuticals	3.7464 of 5 stars	$294.60 +2.0%	$335.75 +14.0%	+80.0%	$5.87B	$290.54M	31.51	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MAZE) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maze Therapeutics (MAZE) Competitors

MAZE vs. XENE, KNSA, PTCT, LGND, and TVTX

How does Maze Therapeutics compare to Xenon Pharmaceuticals?

Summary

How does Maze Therapeutics compare to Kiniksa Pharmaceuticals International?

Summary

How does Maze Therapeutics compare to PTC Therapeutics?

Summary

How does Maze Therapeutics compare to Ligand Pharmaceuticals?

Summary

How does Maze Therapeutics compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE vs. The Competition

Maze Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maze Therapeutics (MAZE) Competitors

MAZE vs. XENE, KNSA, PTCT, LGND, and TVTX

How does Maze Therapeutics compare to Xenon Pharmaceuticals?

Does the media favor XENE or MAZE?

Which has preferable valuation & earnings, XENE or MAZE?

Which has more volatility & risk, XENE or MAZE?

Do insiders & institutionals have more ownership in XENE or MAZE?

Is XENE or MAZE more profitable?

Do analysts recommend XENE or MAZE?

Summary

How does Maze Therapeutics compare to Kiniksa Pharmaceuticals International?

Which has more risk & volatility, MAZE or KNSA?

Do insiders and institutionals believe in MAZE or KNSA?

Is MAZE or KNSA more profitable?

Which has preferable valuation & earnings, MAZE or KNSA?

Does the media prefer MAZE or KNSA?

Do analysts recommend MAZE or KNSA?

Summary

How does Maze Therapeutics compare to PTC Therapeutics?

Which has higher valuation & earnings, MAZE or PTCT?

Does the media refer more to MAZE or PTCT?

Which has more risk & volatility, MAZE or PTCT?

Do analysts recommend MAZE or PTCT?

Is MAZE or PTCT more profitable?

Summary

How does Maze Therapeutics compare to Ligand Pharmaceuticals?

Do analysts recommend MAZE or LGND?

Is MAZE or LGND more profitable?

Does the media refer more to MAZE or LGND?

Which has preferable earnings & valuation, MAZE or LGND?

Which has more risk and volatility, MAZE or LGND?

Do institutionals and insiders have more ownership in MAZE or LGND?

Summary

How does Maze Therapeutics compare to Travere Therapeutics?

Which has higher earnings & valuation, TVTX or MAZE?

Is TVTX or MAZE more profitable?

Does the media prefer TVTX or MAZE?

Which has more risk and volatility, TVTX or MAZE?

Do analysts recommend TVTX or MAZE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE vs. The Competition

Maze Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools